fbpx

News

Lundbeckfonden Ventures News

Cambridge, UK and Indianapolis, US – 21 October 2019: Acacia Pharma Group plc (the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission of the 9,000 Ordinary Shares of...
Cambridge, UK and Indianapolis, US – 1 October 2019: Acacia Pharma Group plc (the “Company), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission in aggregate of 303,841 Ordinary Shares...
Lund, Sweden, 12:00 pm CET, 30 September 2019 – BONESUPPORT HOLDING AB (publ), an emerging leader in orthobiologics for the management of bone voids. During September, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased with 76,800 due to the exercise of warrants. As of 30 September 2019, the number of...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 26 September 2019: Acacia Pharma Group plc (“Acacia Pharma” or “the Company”), a pharmaceutical company developing and commercializing hospital products for US and international markets, announces that the US Food...
SAN DIEGO, Sept. 24, 2019 /PRNewswire/ — Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that preclinical data for fosmanogepix (APX001) will be presented at the upcoming scientific conferences IDWeek 2019 in Washington D.C. from October 2-6, 2019, and the 9th Congress on Trends in Medical Mycology Meeting...
Palma, Spain and San Diego, USA, 23 September 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. In...
Lund, Sweden, 19.00 CET, 18 September 2019 – BONESUPPORT HOLDING AB, listed on Nasdaq Stockholm – an emerging leader in orthobiologics for the management of bone voids announced today that health economic data was presented during the EBJIS conference entitled “The economic burden of osteomyelitis in the UK”. Data shows that the number of patient...
SAN DIEGO, Sept. 16, 2019 /PRNewswire/ — Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that two independent review committees completed their planned safety and efficacy assessment of data from 50% of the planned study population enrolled in the Company’s Phase 2 open-label clinical...
SAN DIEGO, Sept. 16, 2019 /PRNewswire/ — Amplyx Pharmaceuticals Inc. a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that it has executed an exclusive worldwide license agreement with Novartis under which Amplyx has acquired the rights to the Phase 2 anti-BK virus (BKV) monoclonal antibody, MAU868,...
1 2 3 4 5 62

Lundbeckfonden Ventures

Nyheder

Acacia Pharma Group PLC – Issue of Equity on Share Subscription and Licensing agreement With Cosmo Pharmaceuticals
13. January 2020
Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense
13. January 2020
Christine Soden to step down and Gary G. Gemignani to be appointed as new CFO
13. January 2020